Molecular Mechanisms in Malignant Lymphomas - Demonstrators of Personalized Medicine  

For more than 10 years, research teams from all over Germany joint forces to unravel the biological mechanisms which drive the development and progression of malignant, aggressive lymphomas. Today, we have a worldwide unique data collection describing these processes and mathematical models that explain them.

The consortium MMML-demonstrators will use these resources to design novel therapy concepts and develop diagnostic tests that accompany them. Our tests will allow physicians to pick therapies tailored to individual patients. From our mathematical models we will derive completely new therapeutic strategies.

The consortium MMML-demonstrators brings together teams of both computational and experimental biologists and lymphoma experts at eight German sites: (1) Institute of hematology and oncology, University Medical Center Göttingen, (2) Institute for Medical Informatics, Statistics and Epidemiology (IMISE) und Interdisciplinary Centre for Bioinformatics (IZBI), University Leipzig, (3) Institute of Pathology und Institute of Human Genetics, Campus Kiel, (4) Robert Bosch Krankenhaus, Stuttgart, (5) Charité Berlin, (6) German Research Center for Environmental Health (GmbH), Helmholtz Zentrum München, (7) Institute of Pathology, University Würzburg and (8) Institute of Functional Genomic, University of  Regensburg.